Fuadelhibri.ws

• Feeds

  • Entries (RSS)
  • Comments (RSS)

• You are currently browsing the Fuadelhibri.ws blog archives for September, 2010.

• Archives

  • February 2012
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • January 2010
  • December 2009
  • October 2009
  • August 2009
  • July 2009

• Categories

  • Abdul Aziz Said (1)
  • American Society of Hematology (1)
  • Anthrax (6)
  • Arab (2)
  • BioDefense (2)
  • biotech (1)
  • Biothrax (10)
  • Board of directors (2)
  • Business (5)
  • Chief executive officer (48)
  • Chief financial officer (1)
  • Chief Medical Officer (1)
  • Chief operating officer (1)
  • Clinical Research (1)
  • Clinical trial (2)
  • colleagues (1)
  • Dr. Mary Elizabeth King (1)
  • El-Hibri (4)
  • El-Hibri Peace Education Prize (5)
  • Emergent BioSolutions (52)
  • Entrepreneur (2)
  • Ernst & Young (1)
  • Financial Performance (1)
  • Financial Results (2)
  • Food and Drug Administration (11)
  • Foundation (2)
  • fuad el-hibri (53)
  • fuad profiles (1)
  • Health Care (4)
  • Healthcare Conference (3)
  • Infectious disease (4)
  • Investor relations (1)
  • Investors (4)
  • Lymphocytic Leukemia (1)
  • Maryland (2)
  • Music (1)
  • National Health Museum (1)
  • NATO (1)
  • Non-Hodgkin lymphoma (1)
  • North Atlantic Treaty Organization (1)
  • NuThrax (1)
  • Peace Education (3)
  • Pharmaceuticals (1)
  • Resource Center (1)
  • Revenue (1)
  • Scholars Program (1)
  • Seattle (1)
  • Share (1)
  • Shareholder (4)
  • South Africa (1)
  • Tech Council of Maryland (1)
  • Trubion Pharmaceuticals (2)
  • Tuberculosis (2)
  • U.S. Food and Drug Administration (18)
  • Uncategorized (9)
  • United States Department of Defense (1)
  • United States Department of Health and Human Services (2)
  • Vaccine (6)
  • Washington (3)
  • Yale University (3)

Archives

September 2010

Select Month February 2012  (1) November 2011  (1) October 2011  (3) September 2011  (2) August 2011  (2) July 2011  (2) June 2011  (4) May 2011  (2) April 2011  (3) March 2011  (2) February 2011  (2) January 2011  (2) December 2010  (2) November 2010  (2) October 2010  (2) September 2010  (2) August 2010  (4) July 2010  (5) June 2010  (2) May 2010  (2) April 2010  (1) March 2010  (2) January 2010  (1) December 2009  (3) October 2009  (2) August 2009  (2) July 2009  (8) Select Category Abdul Aziz Said  (1) American Society of Hematology  (1) Anthrax  (6) Arab  (2) BioDefense  (2) biotech  (1) Biothrax  (10) Board of directors  (2) Business  (5) Chief executive officer  (48) Chief financial officer  (1) Chief Medical Officer  (1) Chief operating officer  (1) Clinical Research  (1) Clinical trial  (2) colleagues  (1) Dr. Mary Elizabeth King  (1) El-Hibri  (4) El-Hibri Peace Education Prize  (5) Emergent BioSolutions  (52) Entrepreneur  (2) Ernst & Young  (1) Financial Performance  (1) Financial Results  (2) Food and Drug Administration  (11) Foundation  (2) fuad el-hibri  (53) fuad profiles  (1) Health Care  (4) Healthcare Conference  (3) Infectious disease  (4) Investor relations  (1) Investors  (4) Lymphocytic Leukemia  (1) Maryland  (2) Music  (1) National Health Museum  (1) NATO  (1) Non-Hodgkin lymphoma  (1) North Atlantic Treaty Organization  (1) NuThrax  (1) Peace Education  (3) Pharmaceuticals  (1) Resource Center  (1) Revenue  (1) Scholars Program  (1) Seattle  (1) Share  (1) Shareholder  (4) South Africa  (1) Tech Council of Maryland  (1) Trubion Pharmaceuticals  (2) Tuberculosis  (2) U.S. Food and Drug Administration  (18) Uncategorized  (9) United States Department of Defense  (1) United States Department of Health and Human Services  (2) Vaccine  (6) Washington  (3) Yale University  (3) Browse All

• Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine ( September 20, 2010)
• Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine ( September 10, 2010)